As of 2025-07-11, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 73.94 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.3x - 14.5x | 14.0x |
| Forward P/E multiples | 13.6x - 15.6x | 15.0x |
| Fair Price | (934.04) - (996.43) | (997.79) |
| Upside | -304050.6% - -324354.4% | -324795.8% |
| Date | EV/EBITDA |
| 2025-07-09 | -0.21 |
| 2025-07-08 | -0.21 |
| 2025-07-07 | -0.21 |
| 2025-07-03 | -0.21 |
| 2025-07-02 | -0.21 |
| 2025-07-01 | -0.21 |
| 2025-06-30 | -0.21 |
| 2025-06-27 | -0.21 |
| 2025-06-26 | -0.21 |
| 2025-06-25 | -0.21 |
| 2025-06-24 | -0.21 |
| 2025-06-23 | -0.21 |
| 2025-06-20 | -0.21 |
| 2025-06-18 | -0.21 |
| 2025-06-17 | -0.21 |
| 2025-06-16 | -0.21 |
| 2025-06-13 | -0.21 |
| 2025-06-12 | -0.21 |
| 2025-06-11 | -0.21 |
| 2025-06-10 | -0.21 |
| 2025-06-09 | -0.21 |
| 2025-06-06 | -0.21 |
| 2025-06-05 | -0.21 |
| 2025-06-04 | -0.21 |
| 2025-06-03 | -0.21 |
| 2025-06-02 | -0.21 |
| 2025-05-30 | -0.21 |
| 2025-05-29 | -0.21 |
| 2025-05-28 | -0.21 |
| 2025-05-27 | -0.21 |
| 2025-05-23 | -0.21 |
| 2025-05-22 | -0.21 |
| 2025-05-21 | -0.21 |
| 2025-05-20 | -0.21 |
| 2025-05-19 | -0.21 |
| 2025-05-16 | -0.21 |
| 2025-05-15 | -0.21 |
| 2025-05-14 | -0.21 |
| 2025-05-13 | -0.21 |
| 2025-05-12 | -0.21 |
| 2025-05-09 | -0.21 |
| 2025-05-08 | -0.21 |
| 2025-05-07 | -0.21 |
| 2025-05-06 | -0.21 |
| 2025-05-05 | -0.21 |
| 2025-05-02 | -0.21 |
| 2025-05-01 | -0.21 |
| 2025-04-30 | -0.21 |
| 2025-04-29 | -0.21 |
| 2025-04-28 | -0.21 |